{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:46:53Z","timestamp":1758631613334},"reference-count":28,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2006,9,1]]},"DOI":"10.1185\/030079906x120904","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T00:47:39Z","timestamp":1153442859000},"page":"1643-1649","source":"Crossref","is-referenced-by-count":13,"title":["Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension"],"prefix":"10.1185","volume":"22","author":[{"given":"Wendy","family":"Franks","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Brinzolamide Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"CIT0001","first-page":"1268","volume":"120","author":"Heijl A","year":"2002","journal-title":"Early Manifest Glaucoma Trial Group. Reduction of IOP and glaucoma progression results from the Early Manifest Glaucoma Trial. Arch Ophthalmol"},{"key":"CIT0002","first-page":"414","volume":"10","author":"Goldberg I","year":"2001","journal-title":"5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01177-1"},{"key":"CIT0004","first-page":"1177","volume":"112","author":"van der Valk R","year":"2005","journal-title":"A meta-analysis of randomized clinical trials. Ophthalmology"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991772989"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1999.15.323"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1089\/108076801753266802"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200004000-00008"},{"key":"CIT0009","first-page":"701","volume":"120","author":"Kass MA","year":"2002","journal-title":"A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1998.0623"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1981.03930020086007"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00295-3"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50226.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7377.1396"},{"issue":"2","key":"CIT0015","first-page":"S119\u2013S129","volume":"44","author":"DeSantis L","year":"2000","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"CIT0016","first-page":"S147\u2013S153","volume":"44","author":"Silver LH","year":"2000","journal-title":"Surv Ophthalmol"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00095-6"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)83063-5"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(99)00111-3"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701353"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"Azopt\u00e2 summary of product characteristics. 2 June 2005","DOI":"10.1057\/palgrave.jgm.4940075"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01827-5"},{"key":"CIT0023","first-page":"p. 19","author":"Anon","year":"2003","journal-title":"American Academy of Ophthalmology"},{"key":"CIT0024","first-page":"836","volume":"133","author":"O\u2019Connor DJ","year":"2002","journal-title":"Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X38222"},{"key":"CIT0026","first-page":"429","volume":"130","author":"The AGIS Investigators","year":"2000","journal-title":"The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol"},{"key":"CIT0027","unstructured":"Travatan\u00ae summary of product characteristics. 24 October 2003"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(99)00006-3"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079906X120904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T09:07:34Z","timestamp":1597136854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079906X120904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,19]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9,1]]}},"alternative-id":["10.1185\/030079906X120904"],"URL":"https:\/\/doi.org\/10.1185\/030079906x120904","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2006,7,19]]}}}